The
amyloid beta-protein precursor (AbetaPP) is best recognized as the precursor to the Abeta
peptide that accumulates in the brains of patients with
Alzheimer's disease, but less is known about its physiological functions.
Isoforms of AbetaPP that contain a Kunitz-type
serine proteinase inhibitor (KPI) domain are expressed in brain and, outside the CNS, in circulating blood platelets. Recently, we showed that KPI-containing forms of AbetaPP regulates
cerebral thrombosis in vivo (Xu et al., 2005, 2007).
Amyloid precursor like protein-2 (APLP2), a closely related homolog to AbetaPP, also possesses a highly conserved KPI domain. Virtually nothing is known of its function. Here, we show that APLP2 also regulates
cerebral thrombosis risk. Recombinant purified KPI domains of AbetaPP and APLP2 both inhibit the plasma clotting in vitro. In a
carotid artery thrombosis model, both AbetaPP(-/-) and APLP2(-/-) mice exhibit similar significantly shorter times to vessel occlusion compared with wild-type mice indicating a prothrombotic phenotype. Similarly, in an experimental model of
intracerebral hemorrhage, both AbetaPP(-/-) and APLP2(-/-) mice produce significantly smaller
hematomas with reduced brain
hemoglobin content compared with wild-type mice. Together, these results indicate that AbetaPP and APLP2 share overlapping
anticoagulant functions with regard to regulating
thrombosis after cerebral
vascular injury.